NeoTherma Oncology Opens Clinical Study - Wichita, Kansas

NeoTherma Oncology, having achieved both FDA approval for its Investigational Device Exemption for an Early Feasibility Study of the VectRx™ System and institutional review board approval at an east coast National Cancer Institute-designated Cancer Center, has initiated recruitment for a first-in-human trial in patients with pancreatic cancer.